|Bid||60.02 x 900|
|Ask||60.31 x 800|
|Day's range||58.83 - 60.88|
|52-week range||21.06 - 66.47|
|Beta (5Y monthly)||0.50|
|PE ratio (TTM)||41.06|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.
Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.
Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.